Critical Comparison: Immix Biopharma (NASDAQ:IMMX) vs. Syros Pharmaceuticals (NASDAQ:SYRS)

Immix Biopharma (NASDAQ:IMMX) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Analyst Ratings

This is a breakdown of current ratings for Immix Biopharma and Syros Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	0	0	1	0	3.00
Syros Pharmaceuticals	0	0	3	0	3.00

Immix Biopharma currently has a consensus price target of $7.00, suggesting a potential upside of 306.98%. Syros Pharmaceuticals has a consensus price target of $5.00, suggesting a potential upside of 155.10%. Given Immix Biopharma’s higher probable upside, equities research analysts clearly believe Immix Biopharma is more favorable than Syros Pharmaceuticals.

Profitability

This table compares Immix Biopharma and Syros Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-87.09%	-72.07%
Syros Pharmaceuticals	N/A	-850.20%	-94.06%

Volatility and Risk

Immix Biopharma has a beta of 0.12, meaning that its stock price is 88% less volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500.

Insider & Institutional Ownership

11.3% of Immix Biopharma shares are held by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are held by institutional investors. 55.9% of Immix Biopharma shares are held by insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Immix Biopharma and Syros Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$15.43 million	($0.93)	-1.85
Syros Pharmaceuticals	$9.94 million	5.29	-$164.57 million	($4.30)	-0.46

Immix Biopharma has higher earnings, but lower revenue than Syros Pharmaceuticals. Immix Biopharma is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Immix Biopharma beats Syros Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

About Immix Biopharma

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.